The ChemQuest Group, Inc. has announced the addition of Frank Gori as Director, Commercial & Operational Efficiencies in Pharmaceutical, Agricultural and Specialty Chemicals.

In this role, Frank Gori will assist clients through ChemQuest’s methodology and tools in uncovering hidden “value levers” in sales, margin, throughput and cost. 

With over 30 years of experience in Active Pharmaceutical Ingredients (API) industries, Frank Gori is a recognized subject matter expert in producing Active Pharmaceutical Ingredients (API’s) and has manufactured hundreds of Generic API’s and Branded API’s and their intermediates. Moreover, Mr. Gori has produced ten New Molecular Entities and their intermediates for clinical trials, scale-up and commercial launch. In his manufacturing career, Frank Gori managed facilities that produced pharmaceutical API’s, specialty chemicals, biocides, agricultural chemicals and fermented products, and oversaw the manufacturing of the first biosimilar enoxaparin sodium approved by the FDA. Equally important, Frank has earned the reputation as a key strategic partner to Private Equity and Investment Banking interests specializing in M&A, growth and support strategies, and divestiture activities. Known for his well-rounded business acumen, Frank Gori is a skilled facilitator of successful product manufacturing, technology transfer, plant retrofit, site selection, construction, and (CAPEX) capital investment efforts, as well as mergers and acquisitions.

When asked about his recent hiring decision, Dan Murad, president/CEO of ChemQuest, responded that he is elated to welcome Frank Gori. “We feel confident that Frank’s wealth of domestic and international experience spanning diverse industries – building long-lasting customer relationships through effective manufacturing strategies that are executed to deliver end products on schedule and in full – will be a valuable asset to the ChemQuest business model. Frank Gori’s breadth of technical knowledge (and unrivaled track record) in the highly competitive area of regulatory compliance includes managing FDA and other regulatory audits with no adverse findings, no warning letters and no critical highlights. Full implementation and commercial scale-up follow in a timely and cost-effective manner, which I believe will be immeasurably valuable to ChemQuest’s clients.”

The ChemQuest Technology Institute will leverage Frank Gori’s experience in plant and laboratory design and development, to include R&D, technology transfer, Project/Process Engineering and Improvement, EH&S, and QA/QC.

Of his new position at ChemQuest, Frank said “I am excited to put my 30 years of experience and technological achievements in pharmaceutical API’s, specialty chemicals, biocides, agricultural chemicals and fermented products to work for The ChemQuest Group, Inc., to solve diverse manufacturing, compliance and business problems within multiple value chains.  I look forward to my association with this company, my new colleagues and our clients.”